Head-to-head evidence
morf-057 vs SPY001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: α4β7 integrin · full Ulcerative Colitis pipeline
morf-057
Developed by Eli Lilly
NCT05291689 · Phase 2 · completed
This was a single-group, open-label study with 39 participants overall and no placebo or active comparator. The primary clinical/histopathology endpoint was reported as a mean change, but without a comparator there was no formal between-group comparison to establish efficacy.
Next expected readout: May 2027 · NCT07186101 (registry estimate)
SPY001
Developed by Spyre Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07012395 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: morf-057's landscape · SPY001's landscape